PB2133: ASSESSING SAFETY, TOLERABILITY, AND EFFICACY OF SUBCUTANEOUS EPCORITAMAB IN NOVEL COMBINATIONS WITH ANTI-NEOPLASTIC AGENTS IN PATIENTS WITH NON-HODGKIN LYMPHOMA IN A PHASE 1B/2, OPEN-LABEL STUDY
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-06-01
|
| Series: | HemaSphere |
| Online Access: | http://journals.lww.com/10.1097/01.HS9.0000851364.83658.ec |
| _version_ | 1797281272316297216 |
|---|---|
| author | L. H. Sehn I. Avivi J. Brody D. H. Yoon B. M. Elliott S. R. Siddani Y. Bai A. Parikh M. M. Seliem M. H. Dinh A. P. Skarbnik |
| author_facet | L. H. Sehn I. Avivi J. Brody D. H. Yoon B. M. Elliott S. R. Siddani Y. Bai A. Parikh M. M. Seliem M. H. Dinh A. P. Skarbnik |
| author_sort | L. H. Sehn |
| collection | DOAJ |
| first_indexed | 2024-03-07T16:54:30Z |
| format | Article |
| id | doaj.art-a250cd0269f04e32b80e58b2daa03521 |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T16:54:30Z |
| publishDate | 2022-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-a250cd0269f04e32b80e58b2daa035212024-03-03T04:28:46ZengWileyHemaSphere2572-92412022-06-0162004200510.1097/01.HS9.0000851364.83658.ec202206003-02004PB2133: ASSESSING SAFETY, TOLERABILITY, AND EFFICACY OF SUBCUTANEOUS EPCORITAMAB IN NOVEL COMBINATIONS WITH ANTI-NEOPLASTIC AGENTS IN PATIENTS WITH NON-HODGKIN LYMPHOMA IN A PHASE 1B/2, OPEN-LABEL STUDYL. H. Sehn0I. Avivi1J. Brody2D. H. Yoon3B. M. Elliott4S. R. Siddani5Y. Bai6A. Parikh7M. M. Seliem8M. H. Dinh9A. P. Skarbnik101 BC Cancer Centre for Lymphoid Cancer, The University of British Columbia, Vancouver, Canada2 Department of Hematology, Tel-Aviv Sourasky (Ichilov) Medical Center, Tel Aviv, Israel3 Icahn School of Medicine at Mount Sinai, New York, United States of America4 University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea5 Genmab, Princeton6 AbbVie Inc., North Chicago6 AbbVie Inc., North Chicago6 AbbVie Inc., North Chicago6 AbbVie Inc., North Chicago6 AbbVie Inc., North Chicago7 Lymphoma and CLL Program, Novant Health Cancer Institute, Charlotte, United States of Americahttp://journals.lww.com/10.1097/01.HS9.0000851364.83658.ec |
| spellingShingle | L. H. Sehn I. Avivi J. Brody D. H. Yoon B. M. Elliott S. R. Siddani Y. Bai A. Parikh M. M. Seliem M. H. Dinh A. P. Skarbnik PB2133: ASSESSING SAFETY, TOLERABILITY, AND EFFICACY OF SUBCUTANEOUS EPCORITAMAB IN NOVEL COMBINATIONS WITH ANTI-NEOPLASTIC AGENTS IN PATIENTS WITH NON-HODGKIN LYMPHOMA IN A PHASE 1B/2, OPEN-LABEL STUDY HemaSphere |
| title | PB2133: ASSESSING SAFETY, TOLERABILITY, AND EFFICACY OF SUBCUTANEOUS EPCORITAMAB IN NOVEL COMBINATIONS WITH ANTI-NEOPLASTIC AGENTS IN PATIENTS WITH NON-HODGKIN LYMPHOMA IN A PHASE 1B/2, OPEN-LABEL STUDY |
| title_full | PB2133: ASSESSING SAFETY, TOLERABILITY, AND EFFICACY OF SUBCUTANEOUS EPCORITAMAB IN NOVEL COMBINATIONS WITH ANTI-NEOPLASTIC AGENTS IN PATIENTS WITH NON-HODGKIN LYMPHOMA IN A PHASE 1B/2, OPEN-LABEL STUDY |
| title_fullStr | PB2133: ASSESSING SAFETY, TOLERABILITY, AND EFFICACY OF SUBCUTANEOUS EPCORITAMAB IN NOVEL COMBINATIONS WITH ANTI-NEOPLASTIC AGENTS IN PATIENTS WITH NON-HODGKIN LYMPHOMA IN A PHASE 1B/2, OPEN-LABEL STUDY |
| title_full_unstemmed | PB2133: ASSESSING SAFETY, TOLERABILITY, AND EFFICACY OF SUBCUTANEOUS EPCORITAMAB IN NOVEL COMBINATIONS WITH ANTI-NEOPLASTIC AGENTS IN PATIENTS WITH NON-HODGKIN LYMPHOMA IN A PHASE 1B/2, OPEN-LABEL STUDY |
| title_short | PB2133: ASSESSING SAFETY, TOLERABILITY, AND EFFICACY OF SUBCUTANEOUS EPCORITAMAB IN NOVEL COMBINATIONS WITH ANTI-NEOPLASTIC AGENTS IN PATIENTS WITH NON-HODGKIN LYMPHOMA IN A PHASE 1B/2, OPEN-LABEL STUDY |
| title_sort | pb2133 assessing safety tolerability and efficacy of subcutaneous epcoritamab in novel combinations with anti neoplastic agents in patients with non hodgkin lymphoma in a phase 1b 2 open label study |
| url | http://journals.lww.com/10.1097/01.HS9.0000851364.83658.ec |
| work_keys_str_mv | AT lhsehn pb2133assessingsafetytolerabilityandefficacyofsubcutaneousepcoritamabinnovelcombinationswithantineoplasticagentsinpatientswithnonhodgkinlymphomainaphase1b2openlabelstudy AT iavivi pb2133assessingsafetytolerabilityandefficacyofsubcutaneousepcoritamabinnovelcombinationswithantineoplasticagentsinpatientswithnonhodgkinlymphomainaphase1b2openlabelstudy AT jbrody pb2133assessingsafetytolerabilityandefficacyofsubcutaneousepcoritamabinnovelcombinationswithantineoplasticagentsinpatientswithnonhodgkinlymphomainaphase1b2openlabelstudy AT dhyoon pb2133assessingsafetytolerabilityandefficacyofsubcutaneousepcoritamabinnovelcombinationswithantineoplasticagentsinpatientswithnonhodgkinlymphomainaphase1b2openlabelstudy AT bmelliott pb2133assessingsafetytolerabilityandefficacyofsubcutaneousepcoritamabinnovelcombinationswithantineoplasticagentsinpatientswithnonhodgkinlymphomainaphase1b2openlabelstudy AT srsiddani pb2133assessingsafetytolerabilityandefficacyofsubcutaneousepcoritamabinnovelcombinationswithantineoplasticagentsinpatientswithnonhodgkinlymphomainaphase1b2openlabelstudy AT ybai pb2133assessingsafetytolerabilityandefficacyofsubcutaneousepcoritamabinnovelcombinationswithantineoplasticagentsinpatientswithnonhodgkinlymphomainaphase1b2openlabelstudy AT aparikh pb2133assessingsafetytolerabilityandefficacyofsubcutaneousepcoritamabinnovelcombinationswithantineoplasticagentsinpatientswithnonhodgkinlymphomainaphase1b2openlabelstudy AT mmseliem pb2133assessingsafetytolerabilityandefficacyofsubcutaneousepcoritamabinnovelcombinationswithantineoplasticagentsinpatientswithnonhodgkinlymphomainaphase1b2openlabelstudy AT mhdinh pb2133assessingsafetytolerabilityandefficacyofsubcutaneousepcoritamabinnovelcombinationswithantineoplasticagentsinpatientswithnonhodgkinlymphomainaphase1b2openlabelstudy AT apskarbnik pb2133assessingsafetytolerabilityandefficacyofsubcutaneousepcoritamabinnovelcombinationswithantineoplasticagentsinpatientswithnonhodgkinlymphomainaphase1b2openlabelstudy |